NCT00409201

Brief Summary

30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at P25-P50 for phase_1 schizophrenia

Timeline
Completed

Started Mar 2006

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2006

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2006

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

December 7, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 8, 2006

Completed
Last Updated

December 8, 2006

Status Verified

March 1, 2006

First QC Date

December 7, 2006

Last Update Submit

December 7, 2006

Conditions

Schizophrenia

Keywords

schizophreniareboxetinecognitivebehavior

Outcome Measures

Primary Outcomes (1)

  • sans, panss, hamilton, ham-a, calgary, physical examination, cogscan test

Secondary Outcomes (1)

  • esrs, progesterom, sexual functioning, covy, cgi, cgi improved

Interventions

reboxetine adjuvant therapyDRUG

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • schizophrenia all types

You may not qualify if:

  • uti
  • \>65
  • non organic state
  • no depression treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Abarbanel Medical Mental Health Center

Bat Yam, 59100, Israel

RECRUITING

Abarbanel Medical Mental Health Center

Bat Yam, 59100, Israel

RECRUITING

Related Publications (1)

  • Schutz G, Berk M. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int Clin Psychopharmacol. 2001 Sep;16(5):275-8. doi: 10.1097/00004850-200109000-00004.

    PMID: 11552770BACKGROUND

MeSH Terms

Conditions

SchizophreniaBehavior

Condition Hierarchy (Ancestors)

Schizophrenia Spectrum and Other Psychotic DisordersMental Disorders

Study Officials

  • stanislav baranchik, md

    abarbanel mhc

    PRINCIPAL INVESTIGATOR

Central Study Contacts

stanislav baranchik, md

CONTACT

972-3-5552625

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

December 7, 2006

First Posted

December 8, 2006

Study Start

March 1, 2006

Study Completion

November 1, 2006

Last Updated

December 8, 2006

Record last verified: 2006-03

Locations

IL(2)